Please note that this product was withdrawn from the Community Register of designated orphan medicinal products in October 2019 at the end of the 10-year period of market exclusivity.
On 17 October 2003, orphan designation (EU/3/03/171) was granted by the European Commission to PharmaMar S.A., Spain, for trabectedin for the treatment of ovarian cancer.
Ecteinascidin 743 in treatment of ovarian cancer has been authorised in the EU as Yondelis since 28 October 2009.
Treatment of ovarian cancer
|Orphan designation status||
|EU designation number||
|Date of designation||
Polígono Industrial La Mina
Av. de los Reyes 1
28770 Colmenar Viejo
Telephone: (34-91) 846 60 00
Telefax: (34-91) 823 45 03
Documents related to this orphan designation evaluation
For contact details of patients’ organisations whose activities are targeted at rare diseases, see:
EU register of orphan medicines
The list of medicines that have received an orphan designation in the EU is available on the European Commission's website: